Závěrem je vhodné dodat, že všechny v textu uvedené operační metody vedly ke snížení IPSS, IPSS QoL a zvýšení Q_{max} při minimálních změnách sexuálních funkcí. Nežádoucí účinky byly většinou mírné a přechodné. Až dlouhodobé používání v běžné klinické praxi nám ukáže, zda se některá z hodnocených metod stane součástí standardního algoritmu léčby mužů se středně těžkými až těžkými mikčními potížemi způsobenými BHP.

LITERATURA

1. **Srinivasan A, Wang R.** An Update on Minimally Invasive Surgery for Benign Prostatic Hyperplasia: Techniques, Risks, and Efficacy. The world journal of men's health, 2019.
2. **Gilling P, Reuther R, Kahokehr A, Fraundorfer M.** Aquablation-image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU international. 2016; 117(6): 923–929.
3. **Gilling P, Anderson P, Tan A.** Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. The Journal of urology. 2017; 197(6): 1565–1572.
4. **Gilling P, Barber N, Bidair M, et al.** WATER: a double-blind, randomized, controlled trial of Aquablation® vs transurethral resection of the prostate in benign prostatic hyperplasia. The Journal of urology. 2018; 199(5): 1252–1261.
5. **Gilling P, Barber N, Bidair M, et al.** Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Advances in therapy. 2019; 36(6): 1326–1336.
6. **Pham H, Sharma P.** Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. The Canadian journal of urology. 2018; 25(2): 9229.
7. **Woo HH, Chin PT, McNicholas, TA, et al.** Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU international. 2011; 108(1): 82–88.
8. **Chin PT, Bolton DM, Jack G, et al.** Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012; 79(1): 5–11.
9. **Roehrborn CG, Rukstalis DB, Barkin J, et al.** Three year results of the prostatic urethral LIFT study. The Canadian journal of urology. 2015; 22(3): 7772–7782.
10. **Roehrborn CG, Barkin J, Gange SN, et al.** Five year results of the prospective randomized controlled prostatic urethral LIFT study. The Canadian journal of urology. 2017; 24(3): 8802–8813.
11. **Gratzke C, Barber N, Speakman MJ, et al.** Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH 6 prospective, multicentre, randomized study. BJU international. 2017; 119(5): 767–775.
12. **Sønksen J, Barber NJ, Speakman MJ, et al.** Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. European urology. 2015; 68(4): 643–652.
13. **Rukstalis D, Barber NJ, Speakman MJ, et al.** Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate cancer and prostatic diseases. 2018: 1.
14. **Das A, Leong J, Roehrborn C.** Office-based therapies for benign prostatic hyperplasia: a review and update. The Canadian journal of urology. 2019; 26(4S1): 2–7.
15. **Cantrill CH, Zorn KC, Elterman DS, Gonzalez RR.** The Rezūm System – a minimally invasive water vapor thermal therapy for obstructive benign prostatic hyperplasia. The Canadian journal of urology. 2019; 26: 3.
16. **Westwood J, Geraghty R, Jones P, Rai BP, Somani BK.** Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Therapeutic advances in urology. 2018; 10(11): 327–333.
17. **Dixon CM, Cedano ER, Pacik D, et al.** Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Research and reports in urology. 2016; 8: 207.